Sun Pharmaceutical Industries will announce results for the first quarter ended 30 June 2024, on 01 August 2024. These results will also be available on the Company website, www.sunpharma.comPowered by Capital Market - Live News

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 1 August 2024.Powered by Capital Market - Live News

Philogen S.p.A. and Sun Pharmaceutical Industries announced that on June 20 the European Medicines Agency (EMA) validated the submission of the Marketing Authorization Application (MAA) for Nidlegy� , which was finalized on 03 June 2024.Nidlegy� is partnered with Sun Pharma for the treatment of Skin Cancers in Europe, New Zealand and Australia. Both companies jointly made the following announcements:- 23 October 2023 - Phase III PIVOTAL trial met the primary endpoint - 31 May 2024 - Primary results of PIVOTAL presented at ASCO- 04 June 2024 - MAA submission to EMA The data of the Phase III Nidlegy� trial are expected to be published in a peer-reviewed scientific journal in 2024. Powered by Capital Market - Live News

Sun Pharmaceutical Industries announced the successful completion of the merger of Taro Pharmaceutical Industries (NYSE: TARO) (Taro) with its subsidiary. As part of this merger, Sun Pharma acquired all outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates. As a result of the merger, Taro is now a private company and wholly-owned by Sun Pharma. Sun Pharma has been the majority shareholder of Taro since 2010. Powered by Capital Market - Live News

Sun Pharmaceutical Industries announced that it has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company (Takeda) to commercialise Vonoprazan tablets 10 mg, 20 mg in India under the brand name �Voltapraz�. Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders. Under the terms of this agreement, Takeda has granted Sun Pharma non-exclusive patent licensing rights for the commercialization of Vonoprazan in India.Powered by Capital Market - Live News